ARRAYit Technology Used By Researchers at NIH For Important Discovery

SUNNYVALE, Calif., Oct. 8, 2013 /PRNewswire/ -- ARRAYit Corporation (OTCQB: ARYC) reports today that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University have used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.

Pioneering authors Dr. Christopher T. Campbell, Dr. James L. Gulley, Dr. Oyindasola Oyelaran, Dr. James W. Hodge, Dr. Jeffrey Schlom, and Dr. Jeffrey C. Gildersleeve published a paper entitled "Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF" in the 2013 edition of Clinical Cancer Research.  The publication can be read in its entirety at the following link:  http://basicmed.med.ncku.edu.tw/public/project/1298-1363133864-1.pdf.  

The NCI scientists used ARRAYit's patented and proprietary SMP2 and SMP3 microarray printing technology to manufacture glycan microarrays containing miniaturized collections of carbohydrates that selectively react with IgG and IgM antibodies in serum derived from prostate cancer patients.  This important retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advanced prostate cancer.  The NCI microarrays manufactured using ARYC technology consistently stratified the patients into groups with different survival rates, suggesting that the test can be used to empower personalized medicine, which bases treatment options on the characteristics of individual patients.  

The authors emphasize that, "By targeting treatment to likely responders, a predictive method can significantly improve clinical efficacy while simultaneously reducing health care costs."  ARRAYit technology offers the highest testing specificity and sensitivity on the market, which is increasingly allowing doctors to stratify their patients into responders, non-responders and adverse responders, a capability that is empowering safer and more efficacious treatment with life saving medicines.

About ARRAYit Corporation                           

ARRAYit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. ARRAYit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against ARRAYit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.

SOURCE ARRAYit Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED